Literature DB >> 16859581

Development of an integrated prostate cancer research information system.

William K Oh1, Julia Hayes, Carolyn Evan, Judith Manola, Daniel J George, Helen Waldron, Meaghan Donovan, John Varner, John Orechia, Beth Katcher, Diana Lu, Arthur Nevins, Renée L Wright, Lauren Tormey, James Talcott, Mark A Rubin, Massimo Loda, William R Sellers, Jerome P Richie, Philip W Kantoff, Jane Weeks.   

Abstract

BACKGROUND: In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care. PATIENTS AND METHODS: The Prostate Cancer Clinical Research Information System is a relational database. Data are entered from multiple sources, including medical records, institutional laboratory, patient registration, pharmacy systems, and clinician forms. The history, design, and operational characteristics of the database are described. Issues regarding necessary staffing and funding of databases are reviewed.
RESULTS: Four thousand two hundred forty-six patients have information in the Prostate Cancer Clinical Research Information System. Mean age of patients is 62 years, and 89% are white. Seventy-one percent of patients presented at diagnosis with T1 or T2 disease, and 78% had biopsy Gleason scores of <or=7, 8-10 in 18%. Median prostate-specific antigen level at diagnosis was 7 ng/mL, and 77% of patients presented with increased prostate-specific antigen as a trigger symptom. Sixty-four percent of patients presented to our clinic having had no previous treatment for prostate cancer. The majority of approached patients provided consent for collection of clinical data, blood, and tissue. Quality control assessments demonstrate high levels of concordance among data entry personnel.
CONCLUSION: Clinical databases are difficult to implement and maintain; however, they represent a valuable resource, particularly when linked to blood and tissue banks. Elements needed for a successful clinical database include engagement of clinicians, utility for research, and the ability to integrate with legacy systems. As cancer centers develop such databases, lessons learned from each experience should be shared in order to optimize the process.

Entities:  

Mesh:

Year:  2006        PMID: 16859581     DOI: 10.3816/CGC.2006.n.019

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  28 in total

1.  Genome-wide association study of prostate cancer mortality.

Authors:  Kathryn L Penney; Saumyadipta Pyne; Fredrick R Schumacher; Jennifer A Sinnott; Lorelei A Mucci; Peter L Kraft; Jing Ma; William K Oh; Tobias Kurth; Philip W Kantoff; Edward L Giovannucci; Meir J Stampfer; David J Hunter; Matthew L Freedman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-26       Impact factor: 4.254

2.  Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.

Authors:  Miyako Abe; Wanling Xie; Meredith M Regan; Irena B King; Meir J Stampfer; Philip W Kantoff; William K Oh; June M Chan
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

Review 3.  PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.

Authors:  Edoardo Francini; Roberto Petrioli; Giulia Rossi; Letizia Laera; Giandomenico Roviello
Journal:  Tumour Biol       Date:  2014-09-07

4.  Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.

Authors:  Fangfang Qu; Wanling Xie; Mari Nakabayashi; Haitao Zhang; Seong Ho Jeong; Xiaodong Wang; Kazumasa Komura; Christopher J Sweeney; Oliver Sartor; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2016-08-03       Impact factor: 12.531

5.  Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6.

Authors:  Atish D Choudhury; Anna C Schinzel; Maura B Cotter; Rosina T Lis; Katherine Labella; Ying Jie Lock; Francesca Izzo; Isil Guney; Michaela Bowden; Yvonne Y Li; Jinal Patel; Emily Hartman; Steven A Carr; Monica Schenone; Jacob D Jaffe; Philip W Kantoff; Peter S Hammerman; William C Hahn
Journal:  Cancer Res       Date:  2016-11-29       Impact factor: 12.701

6.  SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Ming Yang; Wanling Xie; Elahe Mostaghel; Mari Nakabayashi; Lillian Werner; Tong Sun; Mark Pomerantz; Matthew Freedman; Robert Ross; Meredith Regan; Nima Sharifi; William Douglas Figg; Steven Balk; Myles Brown; Mary-Ellen Taplin; William K Oh; Gwo-Shu Mary Lee; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

7.  Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.

Authors:  Mark M Pomerantz; Lillian Werner; Wanling Xie; Meredith M Regan; Gwo-Shu Mary Lee; Tong Sun; Carolyn Evan; Gillian Petrozziello; Mari Nakabayashi; William K Oh; Philip W Kantoff; Matthew L Freedman
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-02

8.  Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.

Authors:  Xiaosai Yao; Atish D Choudhury; Yvonne J Yamanaka; Viktor A Adalsteinsson; Todd M Gierahn; Christina A Williamson; Carla R Lamb; Mary-Ellen Taplin; Mari Nakabayashi; Matthew S Chabot; Tiantian Li; Gwo-Shu M Lee; Jesse S Boehm; Philip W Kantoff; William C Hahn; K Dane Wittrup; J Christopher Love
Journal:  Integr Biol (Camb)       Date:  2014-02-13       Impact factor: 2.192

9.  Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.

Authors:  R R McKay; L Werner; M Fiorillo; M Nakabayashi; P W Kantoff; M-E Taplin
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-08-09       Impact factor: 5.554

10.  Functional enhancers at the gene-poor 8q24 cancer-linked locus.

Authors:  Li Jia; Gilad Landan; Mark Pomerantz; Rami Jaschek; Paula Herman; David Reich; Chunli Yan; Omar Khalid; Phil Kantoff; William Oh; J Robert Manak; Benjamin P Berman; Brian E Henderson; Baruch Frenkel; Christopher A Haiman; Matthew Freedman; Amos Tanay; Gerhard A Coetzee
Journal:  PLoS Genet       Date:  2009-08-14       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.